Genetic Signatures

ASX Announcement **18 November 2026**

Withdrawal of Resolution 4 following termination of Proposed Merger negotiations with Microba Life Sciences

- Genetic Signatures Limited (ASX: GSS) (**GSS** or the **Company**) has resolved not to proceed with the proposed merger with Microba Life Sciences Limited (ASX: MAP) (**Microba**) (**Proposed Merger**).
- Accordingly, Resolution 4, as set out in the addendum to the Notice of Annual General Meeting released on 23 October 2026 (**Addendum**), has been withdrawn and will not be considered at GSS's AGM on 30 November 2026.

GSS refers to:

- its Notice of Annual General Meeting dated 16 October 2026 (**Notice**) in respect of the Company's Annual General Meeting to be held at 9:00am (Sydney time) on Monday, 30 November 2026 (**AGM**), as amended by:
  - the Addendum; and
  - the further addendum to the Notice dated 12 November 2026 (**Further Addendum**),
- its announcement earlier today advising that GSS would not be proceeding with the Proposed Merger with Microba.

The Addendum provided for the following additional resolution (**Resolution 4**) to be considered by GSS shareholders at the AGM:

> *"That, for the purposes of Listing Rule 7.1 and for all other purposes, the Shareholders approve the proposed issue of the Relevant Securities to the securityholders of Microba Life Sciences Limited ACN 617 096 652 (ASX: MAP) (**Microba**) as consideration under the proposed scheme of arrangement between the Company and Microba, on the terms and conditions set out in the Explanatory Memorandum accompanying the Notice of this Meeting."*

Withdrawal of Resolution 4

In light of the Proposed Merger not proceeding, the GSS Board has determined to withdraw Resolution 4 from the business of the AGM. Accordingly, Resolution 4 will not be put to GSS shareholders at the AGM.

The AGM will otherwise proceed as scheduled to consider Resolutions 1 to 3 as set out in the Notice.

Any votes cast on Resolution 4, whether on the proxy form accompanying the Notice or the replacement proxy form accompanying the Addendum, will be disregarded. Proxy appointments and voting directions validly lodged in respect of Resolutions 1 and 3 remain valid, and shareholders who have already lodged a proxy form do not need to take any further action.

This announcement has been authorised for release by the Board of Genetic Signatures Limited.

– END –

For further information contact:

Mike Aicher
Chair
Genetic Signatures
info@geneticsignatures.com

Genetic Signatures Ltd ABN 30 095 913 205
7 Eliza Street, Newtown NSW 2042
Telephone + 61 (2) 9870 7580

About Genetic Signatures

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

Forward looking statements

This announcement may contain certain 'forward-looking statements' about the financial condition, results of operations and business of GSS, and certain plans and objectives of the Board and management of GSS. Forward looking statements can generally be identified by words such as 'may', 'could', 'believes', 'plan', 'will', 'likely', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These risks and uncertainties may include, but are not limited to, the outcome and effects of the subject matter of this announcement, including the conduct of the AGM. You are cautioned not to place undue reliance on forward looking statements, as actual outcomes may differ materially from them.

Any forward-looking statements, opinions and estimates provided in this announcement necessarily involve uncertainties, assumptions, contingencies and other factors, and unknown risks may arise, many of which are outside the control of GSS. The actual results, achievement or performance of GSS may be materially different from any future results, achievement or performance expressed or implied by such forward looking statements. Forward-looking statements, including without limitation guidance on future plans, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Such forward looking statements speak only as of the date of this announcement. To the maximum extent permitted by law, GSS disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise.

Genetic Signatures Ltd ABN 30 095 913 205
7 Eliza Street, Newtown NSW 2042
Telephone + 61 (2) 9870 7580